Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome-linked gene-expression profiles in meningiomas

Oncologist

Volumn 12, Issue 10, 2007, Pages 1225-1236

  Tabernero Redondo, María Dolores ^a   Espinosa, A Belén ^a   Maillo, Angel ^a   Rebelo, Olinda ^b   Vera, Jaime Fernandez ^a   Sayagues, José María ^c   Merino, Marta ^a   Diaz, Pedro ^a   Sousa, Pablo ^a   Orfao, Alberto ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c Centro de Investigacion del Cancer   (Spain)

Author keywords

Chromosomal abnormalities; Gender iFISH; Gene expression; Meningioma; Microarrays

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CONTROLLED STUDY; CYORF15B GENE; DDX3X GENE; DDX3Y GENE; EIF1AY GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE; GENE EXPRESSION; HUMAN; JARID1D GENE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MONOSOMY; MONOSOMY 22; PRIORITY JOURNAL; RPS4Y1 GENE; SEX CHROMOSOME; USP9Y GENE; X CHROMOSOME; XIST GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SEX CHROMOSOME ABERRATIONS; SEX CHROMOSOMES; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 36148946766     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-10-1225     Document Type: Article

References (67)

1. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: A review. J Neurooncol 1996;29:197-205.
2. Longstreth WT Jr, Dennis LK, McGuire VM et al. Epidemiology of intracranial meningioma. Cancer 1993;72:639-648.
3. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004;63:275-286.
4. Levy WJ Jr, Bay J, Dohn D. Spinal cord meningioma. J Neurosurg 1982;57:804-812.
5. Solero CL, Fornari M, Giombini S et al. Spinal meningiomas: Review of 174 operated cases. Neurosurgery 1989;25:153-160.
6. Zattara-Cannoni H, Gambarelli D, Dufour H et al. Contribution of cytogenetics and FISH in the diagnosis of meningiomas. A study of 189 tumors. Ann Genet 1998;41:164-175.
7. Cerda-Nicolas M, Lopez-Gines C, Perez-Bacete M et al. Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: A study of 60 tumors. Clin Neuropathol 2000;19:259-267.
8. Maillo A, Orfao A, Sayagues JM et al. New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol 2003;21:3285-3295.
9. Maillo A, Orfao A, Espinosa AB et al. Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol 2007;9:438-446.
10. Maillo A, Diaz P, Sayagues JM et al. Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. Cancer 2001;92:377-385.
11. Weber RG, Bostrom J, Wolter M et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94:14719-14724.
12. Dumanski JP, Rouleau GA, Nordenskjold M et al. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 1990;50:5863-5867.
13. Lekanne Deprez RH, Riegman PH, van Drunen E et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 1995;54:224-235.
14. Espinosa AB, Tabernero MD, Maillo A et al. The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res 2006;12:772-780.
15. Carroll RS, Brown M, Zhang J et al. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 2000;6:3570-3575.
16. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: Prognostic considerations. J Neurosurg 1997;86:113-120.
17. Bouillot P, Pellissier JF, Devictor B et al. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: Immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data. J Neurosurg 1994;81:765-773.
18. Wolfsberger S, Doostkam S, Boecher-Schwarz HG et al. Progesterone- receptor index in meningiomas: Correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev 2004;27:238-245.
19. Wahab M, Al-Azzawi F. Meningioma and hormonal influences. Climacteric 2003;6:285-292.
20. Lee E, Grutsch J, Persky V et al. Association of meningioma with reproductive factors. Int J Cancer 2006;119:1152-1157.
21. Smith JS, Quinones-Hinojosa A, Harmon-Smith M et al. Sex steroid and growth factor profile of a meningioma associated with pregnancy. Can J Neurol Sci 2005;32:122-127.
22. Kanaan I, Jallu A, Kanaan H. Management strategy for meningioma in pregnancy: A clinical study. Skull Base 2003;13:197-203.
23. Isla A, Alvarez F, Gonzalez A et al. Brain tumor and pregnancy. Obstet Gynecol 1997;89:19-23.
24. Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 1958;21:89-91.
25. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer 2002;94:1626-1635.
26. Bonito D, Giarelli L, Falconieri G et al. Association of breast cancer and meningioma. Report of 12 new cases and review of the literature. Pathol Res Pract 1993;189:399-404.
27. Kubo M, Fukutomi T, Akashi-Tanaka S et al. Association of breast cancer with meningioma: Report of a case and review of the literature. Jpn J Clin Oncol 2001;31:510-513.
28. Roser F, Nakamura M, Ritz R et al. Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Cancer 2005;104:598-601.
29. Carroll RS, Glowacka D, Dashner K et al. Progesterone receptor expression in meningiomas. Cancer Res 1993;53:1312-1316.
30. Verhagen A, Go KG, Visser GM et al. The presence of progesterone receptors in arachnoid granulations and in the lining of arachnoid cysts: Its relevance to expression of progesterone receptors in meningiomas. Br J Neurosurg 1995;9:47-50.
31. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999;42:109-116.
32. Custer B, Longstreth WT Jr, Phillips LE et al. Hormonal exposures and the risk of intracranial meningioma in women: A population-based case-control study. BMC Cancer 2006;6:152.
33. Korhonen K, Salminen T, Raitanen J et al. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 2006;80:1-7.
34. Roser F, Nakamura M, Bellinzona M et al. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 2004;57:1033-1037.
35. Rubinstein AB, Loven D, Geier A et al. Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg 1994;81:184-187.
36. Adams EF, Schrell UM, Fahlbusch R et al. Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas. J Neurosurg 1990;73:750-755.
37. Grunberg SM, Weiss MH, Spitz IM et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-866.
38. Lamberts SW, Tanghe HL, Avezaat CJ et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 1992;55:486-490.
39. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22-39.
40. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-225; discussion 226-229.
41. Sayagues JM, Tabernero MD, Maillo A et al. Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome-specific probes. Cytometry 2002;50:153-159.
42. Sayagues JM, Tabernero MD, Maillo A et al. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): Is there a relationship between histopathologically benign and atypical/anaplastic lesions? J Mol Diagn 2004;6:316-325.
43. Sayagues JM, Tabernero MD, Maillo A et al. Microarray-based analysis of spinal versus intracranial meningiomas: Different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. J Neuropathol Exp Neurol 2006;65:445-454.
44. Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264.
45. Tibshirani R, Hastie T, Narasimhan B et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-6572.
46. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
47. Eisen MB, Spellman PT, Brown PO et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868.
48. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004;20:3246-3248.
49. Brown CJ, Ballabio A, Rupert JL et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 1991;349:38-44.
50. Thomson R, Pritchard JK, Shen P et al. Recent common ancestry of human Y chromosomes: Evidence from DNA sequence data. Proc Natl Acad Sci U S A 2000;97:7360-7365.
51. Foresta C, Ferlin A, Garolla A et al. High frequency of well-defined Y-chromosome deletions in idiopathic Sertoli cell-only syndrome. Hum Reprod 1998;13:302-307.
52. Whitney AR, Diehn M, Popper SJ et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 2003;100:1896-1901.
53. Xu J, Burgoyne PS, Arnold AP. Sex differences in sex chromosome gene expression in mouse brain. Hum Mol Genet 2002;11:1409-1419.
54. Tang Y, Lu A, Ran R et al. Human blood genomics: Distinct profiles for gender, age and neurofibromatosis type 1. Brain Res Mol Brain Res 2004;132:155-167.
55. Vawter MP, Evans S, Choudary P et al. Gender-specific gene expression in post-mortem human brain: Localization to sex chromosomes. Neuropsychopharmacology 2004;29:373-384.
56. Haslinger C, Schweifer N, Stilgenbauer S et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004;22:3937-3949.
57. Lenburg ME, Liou LS, Gerry NP et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003;3:31.
58. Lahn BT, Page DC. Functional coherence of the human Y chromosome. Science 1997;278:675-680.
59. Ganesan S, Silver DP, Greenberg RA et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 2002;111:393-405.
60. Benoit MH, Hudson TJ, Maire G et al. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol 2007;30:5-17.
61. Piao Z, Malkhosyan SR. Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosomes Cancer 2002;33:262-269.
62. Lachlan KL, Youings S, Costa T et al. A clinical and molecular study of 26 females with Xp deletions with special emphasis on inherited deletions. Hum Genet 2006;118:640-651.
63. Leone PE, Bello MJ, de Campos JM et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999;18:2231-2239.
64. Lamszus K, Kluwe L, Matschke J et al. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999;110:103-110.
65. Murakami M, Hashimoto N, Takahashi Y et al. A consistent region of deletion on 1p36 in meningiomas: Identification and relation to malignant progression. Cancer Genet Cytogenet 2003;140:99-106.
66. Lindblom A, Ruttledge M, Collins VP et al. Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 1994;56:354-357.
67. Logan JA, Seizinger BR, Atkins L et al. Loss of the Y chromosome in meningiomas. A molecular genetic approach. Cancer Genet Cytogenet 1990;45:41-47.